Novozymes Biopharma AB

Novozymes Biopharma AB of Lund, Sweden, and Upperton Ltd. of Nottingham, UK, have been granted a European patent for their targeted drug delivery technology. The patent describes methods of conjugating antibodies and other targeting agents to protein carriers by using a heterobifunctional linker, making it possible to deliver large quantities of drugs to selected sites in the body.





LATEST NEWS

• 3D Holography Integrated Glasses Could Unlock Mixed Reality
  May 2, 2024
• Generative AI Achieves Superresolution with Minimal Tuning
  May 2, 2024
• AmeriCOM Adds President and CEO: People in the News: 5/1/24
  May 1, 2024
• Machine Learning Pushes High-Power Lasing Limits
  May 1, 2024
• IPG Names Industry Veteran Mark Gitin CEO
  Apr 30, 2024
• 16th Biannual Optatec Conference Continues in Frankfurt
  Apr 30, 2024
• Celestial Surface Mapping Tech Combines Established Techniques
  Apr 30, 2024
• TSMC Partnerships Target Integrated Photonics Capabilities
  Apr 30, 2024